Will Biogen’s new Alzheimer’s drug’s burden on Medicare be big, huge, or catastrophic?

The Food and Drug Administration’s decision to grant wide-ranging approval to the controversial, pricey new Alzheimer’s drug Aduhelm will have an eye-popping impact on Medicare finances. The question is exactly how big the impact will be.